One such agent is the nonsteroidal selective ER modulator lasofoxifene, which has shown preclinical promise when used in combination with palbociclib Ibrance in postmenopausal patients with endocrine therapy resistant, locally advanced or metastatic ER positive, HER2 negative breast cancer whose tumors harbor ESR1 mutations priligy over the counter usa You could add those on top of a SERM or after an AI cycle maybe